Market Research Logo

Mixed Dyslipidemia - Pipeline Review, H1 2016

Mixed Dyslipidemia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Mixed Dyslipidemia - Pipeline Review, H1 2016’, provides an overview of the Mixed Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
  • The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mixed Dyslipidemia therapeutics and enlists all their major and minor projects
  • The report assesses Mixed Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia
  • Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Mixed Dyslipidemia Overview
Therapeutics Development
Pipeline Products for Mixed Dyslipidemia - Overview
Mixed Dyslipidemia - Therapeutics under Development by Companies
Mixed Dyslipidemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Mixed Dyslipidemia - Products under Development by Companies
Mixed Dyslipidemia - Companies Involved in Therapeutics Development
Amgen Inc.
CymaBay Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Matinas BioPharma Holdings, Inc.
Pfizer Inc.
Thetis Pharmaceuticals LLC
Mixed Dyslipidemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
bococizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evolocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IONIS-ANGPTL3LRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAT-9001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-8025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-452 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mixed Dyslipidemia - Recent Pipeline Updates
Mixed Dyslipidemia - Dormant Projects
Mixed Dyslipidemia - Discontinued Products
Mixed Dyslipidemia - Product Development Milestones
Featured News & Press Releases
May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting
Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab)
Nov 18, 2015: NICE issues draft guidance on evolocumab for lipid disorder
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol
Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Mixed Dyslipidemia, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Mixed Dyslipidemia - Pipeline by Amgen Inc., H1 2016
Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016
Mixed Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
Mixed Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016
Mixed Dyslipidemia - Pipeline by Pfizer Inc., H1 2016
Mixed Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016
Mixed Dyslipidemia - Dormant Projects, H1 2016
Mixed Dyslipidemia - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Mixed Dyslipidemia, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report